Nanoparticles in the clinic: An update

Bioengineering and Translational Medicine - Tập 4 Số 3 - 2019
Aaron C. Anselmo1, Samir Mitragotri2
1Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
2John A Paulson School of Engineering and Applied Sciences, Harvard University, Wyss Institute of Biologically Inspired Engineering, Cambridge, Massachusetts

Tóm tắt

AbstractNanoparticle drug delivery systems have been used in the clinic since the early 1990's. Since that time, the field of nanomedicine has evolved alongside growing technological needs to improve the delivery of various therapeutics. Over these past decades, newer generations of nanoparticles have emerged that are capable of performing additional delivery functions that can enable treatment via new therapeutic modalities. In the current clinical landscape, many of these new generation nanoparticles have reached clinical trials and have been approved for various indications. In the first issue of Bioengineering & Translational Medicine in 2016, we reviewed the history, current clinical landscape, and clinical challenges of nanoparticle delivery systems. Here, we provide a 3 year update on the current clinical landscape of nanoparticle drug delivery systems and highlight newly approved nanomedicines, provide a status update on previous clinical trials, and highlight new technologies that have recently entered the clinic.

Từ khóa


Tài liệu tham khảo

10.1002/btm2.10003

10.1158/1078-0432.CCR-18-2990

FDA News Release. FDA approves first treatment for certain types of poor‐prognosis acute myeloid leukemia.2017.http://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-certain-types-poor-prognosis-acute-myeloid-leukemia. Accessed August 3 2019.

10.1200/JCO.2010.30.5961

VYXEOS™ Prescription Drug Labeling.2017.http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209401s000lbl.pdf. Accessed August 3 2019.

Banerjee K, 2017, CPX‐351 exposure‐response based on cumulative dose of cytarabine and daunorubicin in patients with newly diagnosed, treatment‐related acute myeloid leukemia (AML) or AML with myelodysplasia‐related changes, Am Soc Hematology, 130, 1360

Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2018 Financial Results.2019.https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-announces-full-year-and-fourth-quarter-2018. Accessed August 20 2019.

10.1002/1097-0142(197501)35:1<98::AID-CNCR2820350115>3.0.CO;2-B

10.1158/0008-5472.CAN-07-6611

10.1056/NEJMoa1716153

10.1038/nbt0918-777

Mullard A, 2018, FDA approves landmark RNAi drug, Nat Rev Drug Discov, 17, 613, 10.1038/nrd.2018.152

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Recent Period Activity.2019.http://investors.alnylam.com/news-releases/news-release-details/alnylam-pharmaceuticals-reports-fourth-quarter-and-full-year-6. Accessed August 3 2019.

10.1016/S1470-2045(19)30326-2

10.1158/1078-0432.CCR-16-1297

Nanobiotix Press Release. Nanobiotix Announces First Ever Radioenhancer to Receive European Market Approval.2019.http://www.nanobiotix.com/download/news_en/2019/PR_Nanobiotix_marquage_CE_04042019_VF.pdf. Accessed August 3 2019.

Hu Y, 2019, Abstract 3225: enhancement of anti‐PD1 and anti‐CTLA4 efficacy by NBTXR3 nanoparticles exposed to radiotherapy, Cancer Res, 79, 3225, 10.1158/1538-7445.AM2019-3225

Rodriguez‐Ruiz ME, 2019, Abstract 536: NBTXR3 potentiate cancer‐cell intrinsic interferon beta response to radiotherapy, Cancer Res, 79, 536, 10.1158/1538-7445.AM2019-536

10.1016/j.ymthe.2019.02.012

10.1038/nnano.2007.387

10.1038/nrd2591

10.1016/j.ijpharm.2005.10.010

10.1021/mp800049w

10.1038/nrc.2016.108

10.1038/nbt.3330

10.1016/S1470-2045(18)30332-2

Merrimack Press Release. Merrimack Stops the Phase 2 HERMIONE Trial of MM‐302 in HER2‐Positive Metastatic Breast Cancer Patients.2016.http://investors.merrimack.com/news-releases/news-release-details/merrimack-stops-phase-2-hermione-trial-mm-302-her2-positive. Accessed August 3 2019.

10.1158/1078-0432.CCR-16-3193

Dicerna Press Release. Dicerna Prioritizes Resources to Advance GalXC™ Product Candidates.2016.http://investors.dicerna.com/news-releases/news-release-details/dicerna-prioritizes-resources-advance-galxctm-product-candidates. Accessed August 3 2019.

10.1016/S1470-2045(17)30621-6

BIND Therapeutics Press Release. BIND Therapeutics Determines Pfizer's $40 Million Bid Is Highest and Best in 363 Auction for Substantially All of BIND's Assets.2016https://www.pfizer.com/sites/default/files/partnering/recent_partnership/BIND-winning-bid-release-072616-FINAL.pdf. Accessed August 3 2019.

10.1016/j.nano.2019.02.021

10.1073/pnas.1906929116

Thông tin
Thông tin xuất bản

Bioengineering and Translational Medicine

Tập 4 Số 3

Thông tin tác giả